ADM has announced that Fibersol, a premier line of soluble prebiotic fibres, has received approval from the Therapeutic Goods Administration (TGA), part of the Australian Department of Health, for use as an active ingredient in biologicals, listed medicines and prescription medicines.
The approval expands Fibersol’s role beyond conventional food and beverage applications into dietary supplements and other regulated health product categories.
"Securing TGA approval for Fibersol marks a significant development for ADM,” said Helen Hu, President of Health & Wellness APAC at ADM.
“It allows our customers to highlight Fibersol’s clinically supported health benefits on packaging, providing clear value in a category where consumer trust is essential."
"In today’s dynamic health and wellness market, regulatory approvals are more than a requirement; they are a mark of credibility."
"With this approval, ADM continues to deliver science-backed solutions that give brands a competitive edge and consumers greater confidence in their choices."
Fibersol has been extensively researched, demonstrating its potential across a wide range of health indications in more than 100 scientific publications.
It is also well-tolerated and versatile, with stability observed under heat, acid, shear and freeze/thaw conditions.
Fibersol has a neutral taste profile, making it easy to incorporate across foods, beverages and dietary supplements.
The prebiotics market in Australia is projected to grow at a CAGR of 17.6% between 2024 and 2030, driven by rising consumer focus on digestive health.
ADM’s latest approval adds to its portfolio of TGA-recognised ingredients, following DE111TM in 2024 and underscores Fibersol’s strong clinical foundation.